Stock 7096 STEMCELL INSTITUTE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings StemCell Institute Inc.

Equities

7096

JP3399640006

Market Closed - Japan Exchange
Other stock markets
 01:59:29 2024-07-03 am EDT 		5-day change 1st Jan Change
1,654 JPY -0.60% Intraday chart for StemCell Institute Inc. -0.66% -22.85%
2023 Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. CI
2023 Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023. CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.

Weaknesses

  • With an expected P/E ratio at 44.58 and 33.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
STEMCELL INSTITUTE INC. Stock StemCell Institute Inc.
-22.85% 106M -
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+20.64% 83.73B
C+
CVS HEALTH CORPORATION Stock CVS Health Corporation
-28.19% 72.21B
B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
-0.35% 26.2B
C+
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+1.39% 17.18B
A-
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-10.31% 17.09B
B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+2.19% 15.18B
A-
NATERA, INC. Stock Natera, Inc.
+78.22% 13.59B
C-
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+79.75% 13.11B
C+
PURE HEALTH HOLDING Stock Pure Health Holding
-22.98% 12.92B - -
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 7096 Stock
  4. Ratings StemCell Institute Inc.